Low-dose chidamide maintenance therapy following allogeneic hematopoietic cell transplantation in T-cell acute lymphoblastic leukemia or lymphomas: a phase II, open-label, multicenter, single-arm trial
{{output}}
Background: Despite allogeneic hematopoietic cell transplantation (allo-HCT), relapse remains a leading cause of treatment failure for patients with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphomas (TCL). Given the... ...
